# Prenatal Stress, the Placenta, and the Developing Brain

OpenMFM | Speaker notes | Reviewed October 23, 2026

## 1. This study informs biology, not an individual baby's prognosis

**Objective:** Establish the presentation's scope.

Study: Verosky and colleagues, Molecular Psychiatry, published October 7, 2026. This is an MFM evidence appraisal, not a fetal-risk calculator. The practical endpoint of this talk is a humane, evidence-based conversation. The study provides useful mechanistic leads and deserves neither dismissal nor extrapolation beyond its measurements.

**References:** R1

## 2. A worried patient's first question is often: “Did I hurt my baby?”

**Objective:** Anchor appraisal in a fictional counseling encounter.

The case is fictional and contains no patient information. Ask what the patient believes the headline means before correcting it. Avoid saying that stress never matters or guaranteeing an unaffected child. Acknowledge uncertainty while removing the unsupported inference that an isolated upsetting event caused injury.

**References:** R1, R4

## 3. Read the headline through three questions

**Objective:** Define learning objectives.

Distinguish stress exposure, perceived stress, anxiety disorders, and depressive symptoms. They overlap but are not equivalent. RNA sequencing counts transcripts; co-expression analysis groups genes whose expression varies together. Neither technique diagnoses psychiatric illness.

**References:** R1, R2, R3

## 4. News coverage compresses several different levels of evidence

**Objective:** Compare reporting with the actual endpoints.

The Neuroscience News summary uses stronger causal and clinical framing than the endpoints support. The institutional release uses more qualified language in its retrieved summary. Its complete page was not accessible, so this appraisal does not attribute detailed claims to unreviewed portions. The publication date is October 7, not the October 1 date in the news article reference.

**References:** R1, R2, R3

## 5. The placenta is an active interface between maternal and fetal physiology

**Objective:** Explain the biological rationale.

The diagram is a hypothesis map, not an observed flow of a measured stress molecule. Endocrine or immune signals could affect both tissues, and a placental response could reflect adaptation rather than the mediator of injury. Correlation between two tissue networks cannot distinguish these alternatives.

**References:** R1

## 6. One paper combines three distinct evidence streams

**Objective:** Prevent species and endpoint conflation.

The experiments use different collection times and assays. Do not treat the single-cell and bulk RNA samples as repeated observations of one cohort. Each animal experiment was one independent experimental cohort, with replication at the dam/litter level. Human observations were not randomized.

**References:** R1

## 7. The mouse exposure was repeated restraint, not ordinary daily worry

**Objective:** Assess exposure validity.

Restraint lasted two hours daily in ventilated tubes during the light phase. The single-cell placental experiment collected tissue at GD17.5, one day after the last stress exposure. The immune-challenge experiment collected at GD16.5 after the last restraint. Mechanical restraint includes physiological features that do not map directly to human self-reported distress.

**References:** R1

## 8. The immune experiment tested four conditions

**Objective:** Explain the factorial design.

Poly(I:C), 20 mg/kg intraperitoneally, activates innate immune responses as a viral mimic. Maternal blood and tissues for cytokines/RT-qPCR were collected three hours later; bulk RNA sequencing was at six hours. This is not an infection transmission, pathogen-clearance, or vaccine-safety experiment.

**References:** R1

## 9. Thousands of sequenced cells still came from six dams

**Objective:** Explain biological replication.

Four placentas per litter, two male and two female when available, were pooled. Pseudobulk aggregates counts by donor and cell type and helps avoid treating thousands of correlated cells as independent pregnancies. Nevertheless, three donors per group constrain precision and sensitivity, particularly for rare cell populations. No FDR-significant abundance shifts were detected; absence of detection is not proof of unchanged composition.

**References:** R1

## 10. The human component studied 20 placentas collected after birth

**Objective:** Describe the translational cohort accurately.

Enrollment required singleton pregnancy at ≤14 weeks. Exclusions included selected chronic conditions, documented illicit substance or tobacco use, and prior preterm birth or preeclampsia. This limits generalization to complex MFM populations. PSS and CES-D were summarized as cumulative areas under the curve with gestational anchors. The study does not supply a diagnostic stress threshold.

**References:** R1

## 11. Stress altered placental gene programs in a cell-specific pattern

**Objective:** Explain the single-cell findings.

Pseudobulk differential-expression and gene-set enrichment analyses support coordinated expression changes in captured populations. Interferon suppression was not uniform across all cells: neutrophils had increased inflammatory signatures. Macrophage subclusters included maternal-associated and fetal Hofbauer populations, with shared antiviral suppression and differing metabolic responses.

**References:** R1

## 12. Lower expression of metabolic genes does not measure placental energy failure

**Objective:** Separate expression from function.

The authors discuss impaired respiration, altered nutrient handling, and endocrine output as hypotheses requiring functional assays. Overall fetal and placental weights were not affected by stress, but the results describe a sex × treatment interaction involving smaller male placentas in the combined exposure condition. Do not simplify this into “all growth outcomes were normal” or infer that normal growth excludes molecular effects.

**References:** R1

## 13. The interferon finding is striking but imprecise

**Objective:** Interpret effect size and uncertainty.

The ratio is stress-to-control maternal plasma IFN-beta concentration after poly(I:C), measured at three hours. It is a post hoc comparison with a broad confidence interval that approaches the null. It does not measure placental protection, fetal injury, infection susceptibility, or an individual patient risk. The display is an original linear-axis plot of the reported estimate, not a reconstruction of raw observations.

**References:** R1

## 14. “Significant here, nonsignificant there” does not prove an interaction

**Objective:** Teach an important statistical caution.

The planned sex-adjusted comparison of placental cellular-response-to-virus scores was p=0.033; the formal interaction was p=0.132. More genes crossing FDR significance in one condition can reflect power and variability as well as biological differences. Describe the pattern as suggestive attenuation while retaining the uncertainty in evidence for effect modification.

**References:** R1

## 15. Mouse fetal-brain gene networks shifted in opposite directions

**Objective:** Explain the paper's central brain finding.

WGCNA means weighted gene co-expression network analysis; a module eigengene summarizes a correlated gene set. Methods report control/saline n=6 (3 female, 3 male), control/poly(I:C) n=6 (2 female, 4 male), stress/saline n=7 (4 female, 3 male), and stress/poly(I:C) n=7 (2 female, 5 male). The figure legend rounds sex counts differently; use the methods counts. One extreme PCA outlier was excluded before downstream analysis. Sex-adjusted module analyses used multiple-testing correction.

**References:** R1

## 16. “Premature maturation” is a biological interpretation of RNA signatures

**Objective:** Avoid presenting an inference as a measured developmental phenotype.

The authors infer a shift from proliferation toward maturation from coordinated expression and earlier literature. This study did not directly demonstrate that specific neurons matured too early or that children later developed a disorder. Prior behavioral findings cited in the introduction and discussion must not be presented as new outcomes from this experiment.

**References:** R1

## 17. Opposite molecular changes do not mean stress protects against infection

**Objective:** Prevent a misleading clinical extrapolation.

Reduced interferon expression is not automatically beneficial. A change could attenuate one inflammatory response while impairing another function; this experiment does not establish those clinical effects. The correct clinical conclusion is that no prevention or infection-management change follows from this pattern alone.

**References:** R1

## 18. The paper does not prove that the placenta mediates stress effects on the brain

**Objective:** Evaluate the proposed causal chain.

Placental PL_M02 correlated with fetal-brain modules and showed a strong poly(I:C) main effect. Stress was not significantly associated with placental modules. Pathway-level stress effects can coexist with a null module-level association because the analyses summarize different structures. Matched tissues and leave-one-condition-out sensitivity analyses improve description but cannot establish directionality or mediation. Placenta-specific perturbation and rescue would provide stronger causal evidence.

**References:** R1

## 19. Human placental results support a hypothesis, not clinical validation

**Objective:** Explain the human association signal.

Human MEpink and MEmagenta were positively associated with PSS-AUC, while MEdarkred and MEturquoise were negatively associated. Their annotations included chromatin/transcription, metabolic/glycosylation, and extracellular-matrix processes. Stress-associated chromatin and RNA-processing themes overlapped with mouse results. Lack of significant CES-D associations does not demonstrate that depression has no biological relevance.

**References:** R1

## 20. Small exploratory networks need independent replication

**Objective:** Assess statistical and technical fragility.

The human cohort is exploratory. Sequential adjustment included maternal age, gestational age at birth, birth weight, and pre-pregnancy BMI, and permutation checks were used. Birth weight could be downstream of exposure, so adjustment does not automatically solve confounding. Placental collection occurred within 12 hours of delivery; RNA integrity ranged 2.1–6 with rRNA-depleted preparation. These issues create potential technical variability, not automatic invalidity. Bulk tissue cell mixtures and residual social, obstetric, or delivery-related factors deserve consideration. Standalone supplements and raw data were not independently audited.

**References:** R1

## 21. The study is strong for discovery and limited for bedside prediction

**Objective:** Provide a balanced appraisal.

Stress allocation was randomized within pregnancy-confirmation cohorts; immune-challenge groups were balanced. Cytokine and RT-qPCR sample processing/acquisition were blinded, whereas downstream RNA analyses were not. No statistical sample-size calculation was performed. Dissociation undercaptures mature multinucleated syncytiotrophoblast; single-nucleus approaches could add information. Selected timepoints cannot distinguish a smaller response from delayed induction or faster resolution.

**References:** R1

## 22. This paper does not create a new fetal test or delivery indication

**Objective:** Define management implications.

This is clinical interpretation of the evidence boundary, not a formal recommendation issued by the research team. No validated clinical stress biomarker or fetal-risk threshold was tested. Continue indicated obstetric assessment for symptoms, growth concerns, or other conditions. Anxiety itself may deserve treatment even when no extra fetal testing is indicated.

**References:** R1, R5

## 23. Patients need support, not the burden of a stress-free pregnancy

**Objective:** Begin the independently usable patient-facing segment.

Introduce this as the patient-facing segment. Avoid framing wellness as a task the patient must perform perfectly to protect the fetus. The responsibility for addressing poverty, unsafe environments, discrimination, or caregiving strain does not belong solely to the pregnant person. Support maternal health because it matters, without using fetal fear as motivation.

**References:** R1, R4

## 24. Ask about distress and connect screening to care

**Objective:** Turn concern into a clinical assessment.

ACOG screening guidance is paired with systems for timely assessment and follow-up. A positive tool is not a diagnosis. Review functioning, psychiatric history, and immediate safety; distinguish research PSS from clinical depression/anxiety instruments. Assessment can also consider other psychiatric or medical contributors as clinically indicated.

**References:** R5

## 25. Practical support starts with the stressor the patient identifies

**Objective:** Address structural and interpersonal burdens.

These are practical implementation examples, not interventions evaluated in the paper. Ask permission before discussing sensitive topics and offer private assessment of safety. Do not automatically involve a partner. A warm handoff to social work or mental-health care is more actionable than a generic instruction to relax.

**References:** R4

## 26. Small routines may help coping without becoming another obligation

**Objective:** Provide achievable self-care options.

Self-care options should be voluntary and feasible. Comfortable breathing need not involve breath-holding or a rigid technique. If an exercise increases distress, stop and try another support. The interactive choice remains only in page memory; it does not save a patient record, send data, or substitute for treatment.

**References:** R4

## 27. Movement can support wellbeing when medically appropriate

**Objective:** Give pregnancy-specific activity advice.

The activity target applies when medical and obstetric contraindications are absent. High-risk patients need individualized advice; the target should not become another source of guilt. Neither the 150-minute target nor exercise as a fetal molecular intervention was tested by Verosky and colleagues.

**References:** R6

## 28. Therapy has stronger clinical support than promises to block stress transmission

**Objective:** Distinguish maternal treatment evidence from fetal-protection claims.

Separate treatment from prevention. Anxiety psychotherapy addresses symptoms/function, whereas the USPSTF Grade B recommendation concerns counseling to prevent perinatal depression in people at increased risk. CBT is cognitive behavioral therapy. The USPSTF page still identified an update in progress when reviewed; this deck uses the final 2019 recommendation rather than a draft.

**References:** R4, R7

## 29. Medication decisions require an individualized risk–benefit discussion

**Objective:** Prevent harmful treatment discontinuation driven by headlines.

The appropriate balance depends on illness severity, history, preferences, medication, and alternatives. This slide deliberately avoids a drug-specific algorithm. ACOG’s patient guidance supports therapy and consideration of medication when needed. Full CPG 5 was access-restricted during review; detailed regimen recommendations are not inferred from inaccessible text.

**References:** R4, R8

## 30. Persistent impairment or immediate danger needs more than self-care

**Objective:** Provide an escalation plan.

A clinician should assess safety directly when indicated. Thoughts of self-harm require prompt risk assessment; immediate intent, inability to remain safe, or other acute danger warrants emergency care. Psychotic symptoms need urgent evaluation. Do not wait for a scheduled routine follow-up when immediate safety is at issue.

**References:** R5, R8

## 31. A one-minute conversation can replace guilt with a plan

**Objective:** Provide a usable counseling script and teach-back.

Use the script flexibly, then listen. Invite teach-back without testing or shaming the patient. Agree on one feasible next step and arrange follow-up based on symptom severity and available support. Avoid promising that a breathing routine or medication will normalize a fetal molecular pathway.

**References:** R1, R4, R5

## 32. Ask your MFM specialist for a plan you can use

**Objective:** Equip patients for shared decisions.

MFM means maternal-fetal medicine: a specialist in higher-risk pregnancies. Invite the patient to choose the questions most relevant to them. This deck provides general education and has no forms, tracking, or transmission of personal information. The clinical visit remains the place for individualized decisions.

**References:** R4, R5, R6, R8

## 33. Clinical pearls: preserve the evidence boundary

**Objective:** Consolidate five scientific takeaways.

These five scientific takeaways protect against the most consequential interpretive errors. They do not negate the study’s discovery value. They define what can responsibly be said when patients ask whether a headline applies to their pregnancy.

**References:** R1

## 34. Clinical pearls: treat distress and reduce blame

**Objective:** Consolidate three actionable takeaways.

These three clinical takeaways complete the eight pearls. Maternal mental-health care is justified without proving that it prevents fetal injury. Follow established obstetric indications and avoid unnecessary testing driven solely by a molecular research headline.

**References:** R1, R4, R5, R6, R7, R8

## 35. Evidence and controversies: the causal and clinical links remain open

**Objective:** Define what would move the field forward.

Alternative explanations include adaptive transcription, developmental timing shifts, and dysfunction. The study cannot fully discriminate among them. Stronger evidence would link repeatable placental signals to measured function and child outcomes while addressing confounding and temporal sequence. No professional disagreement or treatment consensus is invented here.

**References:** R1

## 36. References: the study and its coverage

**Objective:** Enable verification of claims and distinguish source types.

Evidence reviewed October 23, 2026. The supplied 15-page full-text PDF and manuscript text were the primary research sources. The paper’s supplements were considered only as described in the main text; raw data and standalone supplemental files were not independently audited. The full institutional release and some official guideline pages were access-restricted; indexed official summaries and patient guidance supported the clinical recommendations. No treatment algorithms were extrapolated from inaccessible text.

**References:** R1, R2, R3

## 37. References: screening, counseling, and activity

**Objective:** Enable verification of claims and distinguish source types.

Evidence reviewed October 23, 2026. The supplied 15-page full-text PDF and manuscript text were the primary research sources. The paper’s supplements were considered only as described in the main text; raw data and standalone supplemental files were not independently audited. The full institutional release and some official guideline pages were access-restricted; indexed official summaries and patient guidance supported the clinical recommendations. No treatment algorithms were extrapolated from inaccessible text.

**References:** R4, R5, R6

## 38. References: prevention, treatment, and review limits

**Objective:** Enable verification of claims and distinguish source types.

Evidence reviewed October 23, 2026. The supplied 15-page full-text PDF and manuscript text were the primary research sources. The paper’s supplements were considered only as described in the main text; raw data and standalone supplemental files were not independently audited. The full institutional release and some official guideline pages were access-restricted; indexed official summaries and patient guidance supported the clinical recommendations. No treatment algorithms were extrapolated from inaccessible text.

**References:** R7, R8

## Full references

**R1 — Primary research:** Verosky BG, Chen HJ, Anderson JL, et al. Prenatal stress reprograms placental signaling and opposes maternal immune activation effects in the fetal brain. Molecular Psychiatry. Published October 7, 2026. doi:10.1038/s41380-026-03914-8. https://doi.org/10.1038/s41380-026-03914-8

**R2 — Institutional news:** The Ohio State University Wexner Medical Center. Study finds stress during pregnancy may change signals from the placenta tied to fetal brain development. October 13, 2026. https://wexnermedical.osu.edu/mediaroom/pressreleaselisting/placenta-stress-mmr

**R3 — Secondary news:** Neuroscience News. Prenatal Stress Alters the Placenta to Shape Fetal Brain Development. October 13, 2026. https://neurosciencenews.com/prenatal-stress-alters-the-placenta-to-shape-fetal-brain-development/

**R4 — Patient guidance:** American College of Obstetricians and Gynecologists. Anxiety and Pregnancy. Accessed October 23, 2026. https://www.acog.org/womens-health/faqs/anxiety-and-pregnancy

**R5 — Screening guideline:** American College of Obstetricians and Gynecologists. Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum. Clinical Practice Guideline No. 4. Obstet Gynecol. 2023;141:1232–1261. Official implementation summary linked. https://www.acog.org/programs/perinatal-mental-health/patient-screening

**R6 — Activity guidance:** American College of Obstetricians and Gynecologists. Physical Activity and Exercise During Pregnancy and the Postpartum Period. Committee Opinion No. 804. Obstet Gynecol. 2020;135:e178–e188. See also the current Exercise During Pregnancy patient guidance. https://www.acog.org/womens-health/faqs/exercise-during-pregnancy

**R7 — Prevention recommendation:** US Preventive Services Task Force. Perinatal Depression: Preventive Interventions. Final recommendation statement. February 12, 2019. Grade B. Update in progress as of review. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/perinatal-depression-preventive-interventions

**R8 — Treatment guideline:** American College of Obstetricians and Gynecologists. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum. Clinical Practice Guideline No. 5. Obstet Gynecol. 2023;141:1262–1288. https://www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2023/06/treatment-and-management-of-mental-health-conditions-during-pregnancy-and-postpartum